Akash Maniam, Medical Oncologist of Portsmouth Hospitals University NHS Trust, shared on LinkedIn:

“Brilliant. This will change our approach to 1L mCRPC.

OS benefits across all comers for talazoparib + enzalutamide vs enzalutamide, backing up the PFS benefits reported previously. Congratulations Neeraj Agarwal and the entire team for continuing to advance care for a challenging clinical scenario.

This also reinforces the meta-analysis we did Giuseppe Banna quite nicely on PARP inhibitor + ARSI combinations.”

Akash Maniam

Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis

Authors: Carlo Messina, Emilio Francesco Giunta, Alessio Signori, Sara Elena Rebuzzi, Giuseppe Luigi Banna, Akash Maniam, Sebastiano Buti, Carlo Cattrini, Giuseppe Fornarini, Matteo Bauckneht, Alastair Greystoke, Ruth Plummer, Christoph Oing, Pasquale Rescigno

Akash Maniam: Talazoparib and Enzalutamide will change the approach to mCRPC

More posts featuring Akash Maniam on oncodaily.com